Premium
Intradermal injection of incobotulinumtoxinA for face lifting
Author(s) -
Wanitphakdeedecha Rungsima,
Nokdhes YaNin,
Patthamalai Poramin,
Yan Chadakan,
Techapichetvanich Thanya,
Phothong Weeranut,
Eimpunth Sasima,
Manuskiatti Woraphong
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13944
Subject(s) - medicine , contouring , vial , significant difference , intradermal injection , saline , side effect (computer science) , surgery , anesthesia , chemistry , engineering drawing , engineering , computer science , programming language , immunology
Intradermal injection of botulinumtoxinA (BoNT/A) has been used off‐label by many clinicians for the purpose of face‐lifting effect. Some studies on AbobotulinumtoxinA (AboA) demonstrated clinical efficacy on face‐lifting effect when comparing to normal saline solution (NSS). So far, there is no split‐face comparison study on face‐lifting effect of IncobotulinumtoxinA (IncoA). The objective of this study was to compare the face‐lifting effect of IncoA intradermal injection and NSS. Twenty‐two subjects were enrolled and randomly injected with IncoA at 1:6 cc dilution (100 unit or 1 vial in 6 cc of NSS) on one side, and NSS on the other side by using intradermal injection technique. Standardized photographic documentation with 2‐, and 3‐dimentional imaging system (Vectra H1, Canfield Scientific, Inc., Fairfield, NJ) were obtained at baseline, and at 2 weeks after treatment. The face‐lifting effect was graded by the subjects and two blinded dermatologists, using photographic comparison. Side effects were also recorded at the end of the study. Immediate face‐lifting was identified on the side that was treated with IncoA by blinded injectors in 63.6% of patients. Of all subjects, 17 (77.3%) have noticed the improvement of skin laxity on the side that was treated with IncoA at 2 weeks after treatment. The difference in facial contouring volume measured by Vectra H1 imaging system on IncoA side was significantly higher ( P = .033) when comparing to NSS side in patients aged <36 years old. However, there was no statistically significant difference in face‐lifting when comparing between IncoA and NSS evaluated by two blinded dermatologists ( P = 1.00). Facial asymmetry was found in 36.4% of subjects. This study demonstrated the face‐lifting effect of IncoA intradermal injection. Further studies with larger number of subjects and proper method of evaluation should be done to verify these findings.